New Delhi: Shares of
Dishman Carbogen Amcis jumped 8 per cent up in early trade, after veteran investor Mukul Agrawal upped his stake in the company, the latest shareholding pattern shows.
According to the regulatory filing, Agarwal held 40,00,000 equity shares or 2.55 per cent stake in the company on June 30, 2021. He held 25,59,246 equity shares or 1.63 per cent stake in the March 2021 quarter.
Shares of
Dishman Carbogen Amcis surged 8 per cent to Rs 229.85 on Monday in an otherwise weak market. BSE Sensex was trading 382.58 points or 0.72 per cent lower at 52,757.48 at the time of writing this report. The scrip settled at Rs 213.25 on Friday.
sensex: Sensex bleeds 587 points dragged by banks; investors lose Rs 1 16 lakh cr
indiatimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from indiatimes.com Daily Mail and Mail on Sunday newspapers.
Water-Soluble Vitamin D: Better for Those With Malabsorption?
medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.
Study finds new and effective treatment for vitamin D deficiency
eurekalert.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from eurekalert.org Daily Mail and Mail on Sunday newspapers.
India s Ab-drug-conjugate API manufacturer expands to Switzerland with CHF 15 M investment
India s Ab-drug-conjugate API manufacturer expands to Switzerland with CHF 15 M investment 29 April 2021 | News Dishman Carbogen Amcis announces that its subsidiary, Carbogen Amcis AG has entered into a co-investment agreement to create a state-of-the art facility to produce commercial antibody-drug-conjugate API
Photo Credit: Dishman Carbogen Amcis
The company’s subsidiary, Carbogen Amcis AG, pharmaceutical process development and Active Pharmaceutical Ingredient (API) and drug products manufacturing company, announced a joint funding agreement with a longstanding Japan-based customer to build a site extension at the Bubendorf site in Switzerland.
The expansion will be created adjacent to an existing manufacturing facility on the Bubendorf Switzerland Site. This important expansion will incorporate a new production line comprising of two 850 L reactors and one agitated filt